Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · IEX Real-Time Price · USD
4.12
-0.04 (-0.96%)
Dec 29, 2023, 4:30 PM EST - Market closed
Company Description
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom.
The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.
It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada.
Achieve Life Sciences, Inc.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | John A. Bencich M.B.A. |
Contact Details
Address: 22722 29th Dr. Se, Suite 100 Seattle, Washington 98021 United States | |
| Phone | 425-686-1500 |
| Website | achievelifesciences.com |
Stock Details
| Ticker Symbol | ACHV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000949858 |
| CUSIP Number | 004468203 |
| ISIN Number | US0044685008 |
| Employer ID | 95-4343413 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Richard A. B. Stewart | Executive Chairman |
| John A. Bencich M.B.A. | Chief Executive Officer and Director |
| Dr. Cindy Jacobs M.D., Ph.D. | President, Chief Medical Officer and Director |
| Jerry Wan | Principal Accounting Officer |
| Dr. Anthony Clarke | Chief Scientific Officer |
| Jaime Xinos | Executive Vice President of Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 11, 2023 | 8-K | Current Report |
| Nov 9, 2023 | 10-Q | Quarterly Report |
| Nov 9, 2023 | 8-K | Current Report |
| Aug 14, 2023 | 10-Q | Quarterly Report |
| Aug 14, 2023 | 8-K | Current Report |
| Jun 23, 2023 | EFFECT | Notice of Effectiveness |
| Jun 14, 2023 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 9, 2023 | 8-K | Current Report |
| Jun 2, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 25, 2023 | 424B5 | Filing |